Antibody-drug conjugate

1. An antibody-drug conjugate wherein an antitumor compound represented by the following formula:

is conjugated to an antibody via a linker having a structure represented by the following formula:

-L 1 -L 2 -L P -NH—(CH 2 ) n 1 -L a -L b -L c -

wherein the antibody is connected to the terminal of L 1 , the antitumor compound is connected to the terminal of L c with the nitrogen atom of the amino group at position 1 of the antitumor compound as the connecting position,

wherein

L 1 represents -(Succinimid-3-yl-N)—(CH 2 )n 2 -C(═O)— wherein n 2 represents an integer of 2 to 8,

L 2 represents —NH—(CH 2 —CH 2 —O)n 5 -CH 2 —CH 2 —C(═O) or a single bond, wherein n 5 represents an integer of 1 to 6,

L P represents a tetrapeptide residue of GGFG,

—NH—(CH 2 )n 1 -L a -L b -L c - is —NH—(CH 2 ) 3 —C(═O)—, —NH—CH 2 —O—CH 2 —C(═O)—, or —NH—(CH 2 ) 2 —O—CH 2 —C(═O)—,

-(Succinimid-3-yl-N)— has a structure represented by the following formula:

which is connected to the antibody at position 3 thereof and is connected to a methylene group in the linker structure containing this structure on the nitrogen atom at position 1.

2. The antibody-drug conjugate according to claim 1 , wherein n 2 is an integer of 2 to 5, and L 2 is a single bond.

3. The antibody-drug conjugate according to claim 1 , wherein n 2 is an integer of 2 to 5, L 2 is —NH—(CH 2 CH 2 O)n 5 -CH 2 —CH 2 —C(═O)—, and n 5 is 2 or 4.

4. The antibody-drug conjugate according to claim 1 , wherein the structure of the linker is one structure selected from the following group:

-(Succinimid-3-yl-N)—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—(NH-DX)

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—(NH-DX)

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 —O—CH 2 —C(═O)—(NH-DX)

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 —O—CH 2 —C(═O)—(NH-DX)

-(Succinimid-3-yl-N)—CH 2 CH 2 —C(═O)—NH—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—(NH-DX)

-(Succinimid-3-yl-N)—CH 2 CH 2 —C(═O)—NH—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—(NH-DX)

wherein —(NH-DX) represents a group represented by the following formula:

wherein the nitrogen atom of the amino group at position 1 is the connecting position, and -GGFG- represents a peptide residue of -Gly-Gly-Phe-Gly-.

5. The antibody-drug conjugate according to claim 1 , wherein the structure of the linker is one structure selected from the following group:

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 —O—CH 2 —C(═O)—(NH-DX)

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 —O—CH 2 —C(═O)—(NH-DX)

-(Succinimid-3-yl-N)—CH 2 CH 2 —C(═O)—NH—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—(NH-DX)

wherein —(NH-DX) represents a group represented by the following formula:

wherein the nitrogen atom of the amino group at position 1 is the connecting position.

6. The antibody-drug conjugate according to claim 1 , wherein an average number of units of the selected one drug-linker structure conjugated per antibody is in a range of from 2 to 8.

7. The antibody-drug conjugate according to claim 1 , wherein an average number of units of the selected one drug-linker structure conjugated per antibody is in a range of from 3 to 8.

8. The antibody-drug conjugate according to claim 1 , wherein the antibody is an antibody having one or more of a property of recognizing a target cell, a property of binding to a target cell, a property of internalizing in a target cell, and a property of damaging a target cell.

9. The antibody-drug conjugate according to claim 1 , wherein a cell which is targeted by the antibody-drug conjugate is a tumor cell.

10. The antibody-drug conjugate according to claim 1 , wherein the antibody is an anti-A33 antibody, an anti-B7-H3 antibody, an anti-CanAg antibody, an anti-CD20 antibody, an anti-CD22 antibody, an anti-CD30 antibody, an anti-CD33 antibody, an anti-CD56 antibody, an anti-CD70 antibody, an anti-CEA antibody, an anti-Cripto antibody, an anti-EphA2 antibody, an anti-G250 antibody, an anti-MUC1 antibody, an anti-GPNMB antibody, an anti-integrin antibody, an anti-PSMA antibody, an anti-tenascin-C antibody, an anti-SLC44A4 antibody, or an anti-mesothelin antibody.

11. The antibody-drug conjugate according to claim 1 , wherein the antibody is an anti-B7-H3 antibody, an anti-CD30 antibody, an anti-CD33 antibody, or an anti-CD70 antibody.

12. The antibody-drug conjugate according to claim 1 , wherein the antibody is an anti-B7-H3 antibody.

13. A drug containing the antibody-drug conjugate according to claim 1 , or a salt thereof.

14. An antitumor drug and/or anticancer drug containing the antibody-drug conjugate according to claim 1 , or a salt thereof.

15. The antitumor drug and/or anticancer drug according to claim 14 , which is applied to lung cancer, kidney cancer, urothelial cancer, colorectal cancer, prostate cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, stomach cancer, or esophageal cancer.

16. A pharmaceutical composition containing the antibody-drug conjugate according to claim 1 , or a salt thereof as an active component, and a pharmaceutically acceptable formulation component.

17. A method for treating tumor and/or cancer comprising administering the antibody-drug conjugate according to claim 1 , or a salt thereof.

18. A drug-linker intermediate compound represented by the following formula:

Q—(CH 2 )n Q -C(═O)-L 2a -L P -NH—(CH 2 )n 1 -L a -L b -L c -(NH-DX)

wherein Q represents (maleimid-N-yl)-

n Q represents an integer of 2 to 8,

L 2a represents —NH—(CH 2 —CH 2 —O)n 5 -CH 2 —CH 2 —C(═O)— or a single bond,

wherein n 5 represents an integer of 1 to 6,

L P represents a tetrapeptide of GGFG,

—NH—(CH 2 )n 1 -L a -L b -L c - is —NH—(CH 2 ) 3 —C(═O)—, —NH—CH 2 —O—CH 2 —C(═O)—, or —NH—(CH 2 ) 2 —O—CH 2 —C(═O)—,

(maleimid-N-yl)- is a group represented by the following formula:

wherein the nitrogen atom is a connecting position,

and

—(NH-DX) is a group represented by the following formula:

wherein the nitrogen atom of the amino group at position 1 is a connecting position.

19. The drug-linker intermediate compound according to claim 18 , wherein n Q is an integer of 2 to 6.

20. The drug-linker intermediate compound according to claim 18 , wherein

n Q is an integer of 2 to 5, and

L 2a is a single bond.

21. The drug-linker intermediate compound according to claim 18 , wherein

n Q is an integer of 2 to 5,

L 2a is —NH—(CH 2 —CH 2 —O)n 5 -CH 2 —CH 2 —C(═O)—, and

n 5 is an integer of 2 to 4.

22. The drug-linker intermediate compound according to claim 21 , wherein n 5 is an integer of 2 or 4.

23. A compound of the following:

(maleimid-N-yl)-CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—(NH-DX)

(maleimid-N-yl)-CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—(NH-DX)

(maleimid-N-yl)-CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—(NH-DX)

(maleimid-N-yl)-CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—(NH-DX)

(maleimid-N-yl)-CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 —O—CH 2 —C(═O)—(NH-DX)

(maleimid-N-yl)-CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 —O—CH 2 —C(═O)—(NH-DX)

(maleimid-N-yl)-CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 —O—CH 2 —C(═O)—(NH-DX)

(maleimid-N-yl)-CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 —O—CH 2 —C(═O)—(NH-DX)

(maleimid-N-yl)-CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 —O—CH 2 —C(═O)—(NH-DX)

(maleimid-N-yl)-CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 —O—CH 2 —C(═O)—(NH-DX)

(maleimid-N-yl)-CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 —O—CH 2 —C(═O)—(NH-DX)

(maleimid-N-yl)-CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 —O—CH 2 —C(═O)—(NH-DX)

(maleimid-N-yl)-CH 2 CH 2 —C(═O)—NH—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—(NH-DX) (maleimid-N-yl)-CH 2 CH 2 —C(═O)—NH—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—(NH-DX), or

(maleimid-N-yl)-CH 2 CH 2 —C(═O)—NH—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—(NH-DX)

wherein (maleimid-N-yl)- is a group represented by the following formula:

wherein the nitrogen atom is a connecting position, and

—(NH-DX) is a group represented by the following formula:

wherein the nitrogen atom of the amino group at position 1 is a connecting position.

24. A compound of the following:

(maleimid-N-yl)-CH 2 CH 2 —C(═O)—NH—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—(NH-DX),

(maleimid-N-yl)-CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 —O—CH 2 —C(═O)—(NH-DX) or

(maleimid-N-yl)-CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 —O—CH 2 —C(═O)—(NH-DX),

wherein (maleimid-N-yl)- is a group represented by the following formula:

wherein the nitrogen atom is a connecting position, and

—(NH-DX) is a group represented by the following formula:

wherein the nitrogen atom of the amino group at position 1 is a connecting position.

25. A linker represented by the following formula:

-L 2 -L P -NH—(CH 2 ) n 1 -L a -L b -L c -

for obtaining an antibody-drug conjugate in which a drug is conjugated to an antibody via the linker,

wherein L 1 is a connecting position for the antibody, L c is a connecting position for an antitumor compound,

wherein

L 1 represents -(Succinimid-3-yl-N)—(CH 2 )n 2 -C(═O)—,

wherein n 2 represents an integer of 2 to 8,

L 2 represents —NH—(CH 2 —CH 2 —O)n 5 -CH 2 —CH 2 —C(═O) or a single bond, wherein n 5 represents an integer of 1 to 6,

L P represents a tetrapeptide residue of GGFG,

—NH—(CH 2 )n 1 -L a -L b -L c - is —NH—(CH 2 ) 3 —C(═O)—, —NH—CH 2 —O—CH 2 —C(═O)—, or —NH—(CH 2 ) 2 —O—CH 2 —C(═O)—,

-(Succinimid-3-yl-N)— has a structure represented by the following formula:

which is connected to the antibody at position 3 thereof and is connected to a methylene group in the linker structure containing this structure on the nitrogen atom at position 1.

26. The antibody-drug conjugate according to claim 5 , wherein the structure of the linker is:

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 —O—CH 2 —C(═O)—(NH-DX).

27. The antibody-drug conjugate according to claim 5 , wherein the structure of the linker is:

-(Succinimid-3-yl-N)—CH 2 CH 2 —C(═O)—NH—CH 2 CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—(NH-DX).

28. The compound according to claim 24 , wherein the structure of the compound is:

(maleimid-N-yl)-CH 2 CH 2 —C(═O)—NH—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—(NH-DX).

29. The compound according to claim 24 , wherein the structure of the compound is:

(maleimid-N-yl)-CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 —O—CH 2 —C(═O)—(NH-DX).

30. The compound according to claim 24 , wherein the structure of the compound is:

(maleimid-N-yl)-CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 —O—CH 2 —C(═O)—(NH-DX).

31. The linker according to claim 25 , which is selected from the following group, provided that the left terminal is a connecting position with the antibody and the right terminal is a connecting position with the antitumor compound:

-(Succinimid-3-yl-N)—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—

-(Succinimid-3-yl-N)—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 —O—CH 2 —C(═O)—

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 —O—CH 2 —C(═O)—

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 —O—CH 2 —C(═O)—

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 —O—CH 2 —C(═O)—

-(Succinimid-3-yl-N)—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 —O—CH 2 —C(═O)—

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 —O—CH 2 —C(═O)—

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 —O—CH 2 —C(═O)—

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 —O—CH 2 —C(═O)—

-(Succinimid-3-yl-N)—CH 2 CH 2 —C(═O)—NH—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—

-(Succinimid-3-yl-N)—CH 2 CH 2 —C(═O)—NH—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—,and

-(Succinimid-3-yl-N)—CH 2 CH 2 —C(═O)—NH—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—.

32. The linker according to claim 25 , which is selected from the following group, provided that the left terminal is a connecting position with the antibody and the right terminal is a connecting position with the antitumor compound:

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 —O—CH 2 —C(═O)—

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 —O—CH 2 —C(═O)—, and

-(Succinimid-3-yl-N)—CH 2 CH 2 —C(═O)—NH—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—.

33. The linker according to claim 25 , which is selected from the following group, provided that the left terminal is a connecting position with the antibody and the right terminal is a connecting position with the antitumor compound:

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 —O—CH 2 —C(═O)—.

34. The linker according to claim 25 , which is selected from the following group, provided that the left terminal is a connecting position with the antibody and the right terminal is a connecting position with the antitumor compound:

-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 —O—CH 2 —C(═O)—.

35. The linker according to claim 25 , which is selected from the following group, provided that the left terminal is a connecting position with the antibody and the right terminal is a connecting position with the antitumor compound:

-(Succinimid-3-yl-N)—CH 2 CH 2 —C(═O)—NH—CH 2 CH 2 O—CH 2 CH 2 O—CH 2 CH 2 —C(═O)-GGFG-NH—CH 2 CH 2 CH 2 —C(═O)—.